CORTICOTROPIN RELEASING FACTOR/SEROTONERGIC INTERACTIONS

描述：（改编自申请人摘要）

DESCRIPTION: (Adapted From The Applicant's Abstract) Corticotropin-releasing factor (CRF) and serotonin (5-HT) systems have been independently implicated in stress-related psychiatric disorders. We demonstrate potent effects of CRF on forebrain 5-HT release and activity of putative 5-HT dorsal raphe nucleus (DRN) neurons. Taken with findings of CRF innervation and expression of CRF receptors in the DRN, these results suggest that endogenous CRF acts within the DRN to regulate forebrain 5-HT function. The following AIMS test this hypothesis by characterizing CRF-5-HT interactions at an ultrastructural, electrophysiological and neurochemical level, identifying conditions that engage these interactions, and determining whether CRF effects within the DRN play a role in a behavior associated with depression. 1) Characterize and quantify CRF effects on extracellular 5-HT levels in terminal regions and DRN neuronal activity. Dose-response curves will be generated for CRF effects (administered i.c.v. or intraraphe) on 5-HT release in lateral septum, amygdala and cortex and DRN neuronal activity. The efficacy of CRF antagonists (administered i.c.v., systemically or intraraphe) to prevent these effects will be determined. This AIM will reveal whether CRF acts directly within the DRN to alter forebrain 5-HT release, whether effects on 5-HT release are regionally specific and the CRF receptor subtype involved; 2) Identify physiological conditions during which endogenous CRF impacts on DRN-5-HT systems. The ability of CRF antagonists (administered i.c.v. or intraraphe) to prevent changes in forebrain 5-HT release elicited by different challenges will be determined. This AIM will reveal conditions during which CRF-5-HT interactions are engaged; 3) Characterize cellular substrates for CRF-5-HT interactions in the DRN and identify CRF afferents to the DRN. Interactions between CRF terminals and 5-HT processes in the DRN will be visualized at the ultrastructural level using dual label immunohistochemistry and electron microscopy. Neuronal tract tracing will be used to identify CRF afferents to the DRN. This AIM will reveal potential cellular mechanisms underlying CRF-5-HT interactions and provide a map detailing how CRF systems link to the DRN; 4) Elucidate the role of CRF-5-HT interactions in a behavior associated with depression. The hypothesis that CRF release in the DRN and subsequent inhibition of 5-HT forebrain release underlie behavioral immobility associated with swim stress will be tested. The effects of CRF or CRF antagonists (administered i.c.v. or intraraphe) on behavior in the forced swim test will be determined. This AIM will reveal potential pathophysiological consequences of CRF-5HT interactions.